Strengths and limitations of phase 3 trial with bempedoic acid - PACE-CME

Strengths and limitations of phase trial with bempedoic acid

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Do personalized reminders to clinicians result in higher use of high-intensity statins?
Do personalized reminders to clinicians result in higher use of high-intensity statins?
ACC.23
Do personalized reminders to clinicians result in higher use of high-intensity statins?
- Prof. Salim Virani, MD, PhD
Well-designed EHR tools can improve prescribing of MRA in HFrEF
Well-designed EHR tools can improve prescribing of MRA in HFrEF
ACC.23
Well-designed EHR tools can improve prescribing of MRA in HFrEF
- Amrita Mukhopadhyay, MD
Causal AI can substantially improve the value of polygenic risk score for CVD
Causal AI can substantially improve the value of polygenic risk score for CVD
ACC.23
Causal AI can substantially improve the value of polygenic risk score for CVD
- Prof. Brian Ference, MD
Findings of a phase 2 trial with aldosteron synthase inhibitor in hypertension
Findings of a phase 2 trial with aldosteron synthase inhibitor in hypertension
ACC.23
Findings of a phase 2 trial with aldosteron synthase inhibitor in hypertension
- Deepak Bhatt, MD